Literature DB >> 9517797

Antiphospholipid antibodies in eclamptic women.

B Kaleli1, I Kaleli, E Aktan, C Turan, F Akşit.   

Abstract

Our purpose was to determine the prevalence of antiphospholipid antibodies (APA) in eclamptic women as well as the rates of intrauterine growth retardation (IUGR) and fetal death in APA-positive and -negative eclamptic women. Thirty-six eclamptic and 30 healthy pregnant women were enrolled in this study. APA in those groups were determined. The prevalences of IUGR and fetal death were determined in APA-positive and -negative eclamptic women. In the eclamptic group, APA were positive in 9 out of 36 patients (25%), where as only 2 out of 30 controls (6.7%) were positive (p < 0.05). Fetal death was encountered in 4 out of 9 (44.4%) APA-positive eclamptic women; this was a significantly larger proportion than that for APA-negative eclamptic women (1/27; p < 0.01). The rates of IUGR in APA-positive and -negative eclamptic women were not significantly different (p > 0.05). Similar conclusions about our results could also be made, when weakly positive anticardiolipin antibodies were regarded as negative in our study group and controls. Our study suggests that positive levels of APA in eclamptic women increase the risk for intrauterine fetal death.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517797     DOI: 10.1159/000009930

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  3 in total

Review 1.  Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis.

Authors:  J E Salmon; G Girardi; V M Holers
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  Update on the management of the pregnant patient with antiphospholipid antibody.

Authors:  L R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

3.  Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study.

Authors:  K J Gibbins; A E Tebo; S K Nielsen; D W Branch
Journal:  Lupus       Date:  2018-07-20       Impact factor: 2.911

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.